Skip to content

A CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF "IRUKAARA PARPAM" IN PATIENT WITH KIDNEY STONE

A CLINICAL STUDY ON AZHAL KALLADAIPPU (RENAL CALCULI)AND THE DRUG OF CHOICCE IS IRUKAARA PARPAM (INTERNAL).

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/08/004931
Enrollment
40
Registered
2014-08-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- AZHAL KALLADAIPPU(RENAL CALCULI)

Interventions

Intervention1: IRUKAARA PARPAM: IT IS A MINERAL FORMULATION,130Mg with HONEY,BID,ORAL ROUTE ADMINISTRATION,24days Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

NATIONAL INSTITUTE OF SIDDHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients who are having the classical symptoms of abdominal pain and distensión, pain from loin to groin, pain in urethra, agonizing pain, dysuria, oliguria, yellow coloured urination, burning micturition, haematuria, nausea and vomiting. • Stone size: >=4mm and • Patient with renal calculus detected on X-ray KUB or USG abdomen. • History of Recurrence of Renal calculi. • Patient willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 24days but can opt out of the trial of his/her own conscious discretion. • Patients who are willing to take Ultrasonography Investigation (USG- abdomen / KUB) and provide blood and urine samples for laboratory investigation.

Exclusion criteria

Exclusion criteria: • Stone size 10mm • Pregnancy and lactation • Presence of any associated severe systemic illness, e.g.CA • Patient taking any other lithotriptic agent in the recent past • History of Diabetes/ Hypertension • Renal diseases • Cardiac diseases

Design outcomes

Primary

MeasureTime frame
1complete clearance/ reduction in the size of renal calculus in X-ray KUB or USG abdomen.Timepoint: 24 DAYS

Secondary

MeasureTime frame
2. Complete reduction of clinical symptoms and improvement in the lab investigationTimepoint: 24DAYS

Countries

India

Contacts

Public ContactDR S MOHAN

NATIONAL INSTITUTE OF SIDDHA

drlakshmiramaswamy@gmail.com9444466880

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026